Among Palestinian women, the incidence of breast cancer is lower than among European and North American women, yet many Palestinian breast cancer patients have relatives who also developed the disease. 1 Familial clustering of breast cancer in an otherwise low-incidence population could reflect clustering of nongenetic risk factors, or genetic predisposition, or both. In order to evaluate the genetic contribution to breast cancer in the Palestinian population, we undertook to determine the frequency, spectrum and consequences of damaging mutations in breast cancer genes among Palestinian patients.
Patients and Methods

Patients
Participants in the project were Palestinian women treated for primary invasive breast cancer between 2008 and 2016 at Augusta Victoria Hospital, Arab Care Hospital Ramallah, El Husseini-Beit Jala Government Hospital, or Share Zedek Medical Center. Patients consenting to participate in the study were interviewed about their family history of cancers, asked for permission to review medical records of their breast cancer diagnosis and treatment, and asked to contribute 8.5 ml peripheral blood sample for genomic DNA extraction. Controls were healthy Palestinian maternity patients from Holy Family Hospital, Bethlehem. Institutional review boards of all participating institutions approved the project. For genomic analysis, the cohort of subjects was divided into two groups based on age at diagnosis and family history. The "discovery series" included all patients diagnosed at age 40 or younger or with family history of breast or ovarian cancer in a first or second degree relative. The "older-onset, sporadic patient series" included all other patients; i.e., those diagnosed after age 40 and with no close relative with breast or ovarian cancer.
Genomics
For patients in the discovery series, germline DNA extracted from blood was sequenced using breast and ovarian cancer gene panel (BROCA), a targeted capture and multiplexed massively parallel sequencing panel that enables detection of all classes of mutations in all known breast cancer genes. 2, 3 Genes included in this project were ATM, BRCA1-associated RING domain 1 (BARD1), Breast Cancer 1 (BRCA1), BRCA2, BRIP1, CHEK2, FAM175A/ABRAXAS, MRE11A, NBN, PALB2, PTEN, RAD51C, RAD51D, SLX4/FANCP, TP53 and XRCC2. Sequencing was carried out to minimum 2003 coverage and reads aligned to the human reference genome (hg19). Variants were identified using genomic analysis tool kit (GATK37) and Pindel after indel realignment and base quality recalibration, and single nucleotide variants, indels; copy number variants (CNVs) were detected and annotated as previously described. [2] [3] [4] [5] Missense mutations were included only if previously reported with experimental evidence to be damaging to protein function. For samples with large deletions that extended beyond the genomic regions targeted by BROCA, exact breakpoints were determined by whole genome sequencing, carried out to median minimum 30-fold coverage on Illumina HiSeq X-Ten instruments (Macrogen). Format for sequence data with quality (FASTQ) reads of whole genome sequence were evaluated with manta structural variant caller (MANTA-SV) to identify deletion breakpoints. 6 As damaging mutations were identified in the discovery series, the 422 subjects in the older-onset, sporadic patient series and 300 adult Palestinian controls were genotyped for each variant, either by Sanger sequencing or with single nucleotide polymorphism (SNP)-type assays (Fluidigm). For mutations occurring in more than one patient, the possibility of shared ancestry was evaluated by haplotype analysis using short tandem repeat (STR) markers flanking the mutation. Statistical comparisons were based on two-tailed v 2 tests, Fisher exact tests or tests of the difference between independent proportions, as appropriate.
Results
Clinical features of the patients and their tumors
The total study sample included 875 Palestinian women with a diagnosis of invasive breast cancer, including 453 women in the discovery series and 422 women in the older-onset sporadic patient series. Demographic features of the subjects are shown in Table 1 . Pathology records were sought for the patients in the discovery series. Tumor stage, grade and hormonal status were available for 61% (278/453), 36% (161/ 453) and 49% (220/453) of these patients, respectively. Among patients with pathology data, the distribution of tumor stage was 9% Stage I, 45% Stage II, 41% Stage III and 5% Stage IV. The distribution of tumor grade was 4% grade I, 45% Grade II and 51% Grade III. Of tumors with hormone receptor profiles, 20% were triple negative (TNBC).
Burden of mutations in breast cancer genes
For the patients in the discovery series, genomic analysis using BROCA of all known breast cancer genes revealed that 13.5% (61/453) of patients carried an unambiguously damaging germline mutation in any of eleven different genes ( Table  2 and supporting information Table S1 ). For BRCA1 and BRCA2, 6.8% (31/453) of patients carried a damaging mutation. Carrier frequency was highest in patients with both young onset of breast cancer and positive family history: 27% (21/79) among patients with both positive family history and young age at diagnosis, 13% (25/188) among patients with a positive family history but diagnosed after age 40, and 8.0% (15/186) among patients diagnosed by age 40 but with negative family history (p 5 0.0002). Carrier frequencies were highest for BRCA1 (11 patients) and BRCA2 (20), followed by TP53 (9), ATM (6), CHEK2 (5), BARD (4), BRIP1 (2) MRE11A (1), PALB2 (1), PTEN (1) and XRCC2 (1) (Fig. 1) . Four previously unreported variants of unknown significance were also identified, one each in ATM, BRIP1, CHEK2 and FAM175A (supporting information Table S2 ). Among patients for whom tumor hormone receptor status was known, 9% (4/44) of those with TNBC compared to 2% (3/ 176) of those with receptor positive breast cancer carried a pathogenic mutation in BRCA1 (p 5 0.03). The relationship between TNBC and BRCA1 mutation status is similar in this population to that observed elsewhere.
7 Across all genes, 41 different damaging mutations were identified in the mutation discovery series. Genotyping these 41 mutations in the general population series yielded 1.0% (4/422) additional mutation carriers. One mutation appeared in controls: BARD1 p.Q735X in two cancer-free women.
Of the 41 different mutations identified in the participants, 30 were present in only one family and 11 were present in more than one apparently unrelated patient. The most frequent recurrent mutation in BRCA1 or BRCA2 was BRCA2 c.2482delGACT, originally reported from a Palestinian patient living in Saudi Arabia 8 and found in 0.7% (6/875) of all index patients. The single most frequent mutation in any gene was TP53 p.R181C, previously reported in Palestinian families 9 and found in 1.0% (9/875) of all index patients. TP53 p.R181C is described more fully below. Collectively, the 11 recurrent mutations explained 59% (36/61) of the patients with mutations in the fully evaluated discovery series.
What's new? Although breast cancer incidence is low in Palestine compared to Europe or North America, most Palestinian breast cancer patients have a family history of breast or ovarian cancer or were diagnosed at a young age. Among familial and young onset patients, 13% carry a germ-line pathogenic mutation in one of eleven breast cancer genes. Most mutations were in BRCA1 or BRCA2, but the single most frequent mutation was TP53 p.R181C, which predisposes specifically to breast cancer.
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Haplotype analysis showed that recurrent mutations originated on shared ancestral haplotypes. Furthermore, of the 41 different mutations, 68% (28/41) have been reported previously and 32% (13/41) are new to this study (supporting information Table S1 ). Of the mutations previously reported in the literature, BRCA1 p.E1373X, BRCA2 c.2482delGACT and TP53 p.R181C have been reported in other Palestinian families. 7, 8, 10 BRCA1 p.C44F and BRCA1 p.W1815X were originally described in Lebanese families. 11,12 XRCC2 p.
R215X was originally described in a child with Fanconi anemia living in Saudi Arabia. 13 These mutations may be Middle
Eastern "founder alleles."
Genomic deletion of the BRCA1 promoter
Whole genome sequencing of patient MK1ES revealed a 29 kb genomic deletion of the BRCA1 promoter region with breakpoints that are specific to this Palestinian family (supporting information Fig. S1 ). In other studies from our lab, we have encountered other deletions of the BRCA1 promoter region, with breakpoints within a few kb of the breakpoints of this allele, in four other families of various European ancestries. The 35 kb genomic region that includes the BRCA1 promoter is both segmentally duplicated and densely packed with repetitive sequences. This region may be a hotspot for both germline and somatic deletion leading to loss of function of BRCA1.
Founder mutation in TP53
The mutation with the highest frequency in the cohort was TP53 p.R181C (c.541G > A) at chr17:7,578,389 (Fig. 2) This missense appeared in nine of the 453 patients in the discovery series versus zero of 300 Palestinian controls (p 5 0.014). The variant is classified as "likely pathogenic" on ClinVar and is not present on ExAC. Seven of the nine families with the mutation are from Hebron. Although the patients are not aware of any direct relationship among them, the mutation occurs on a haplotype of at least 2 MB shared by all nine families, indicating a common ancestor (supporting information Figs. S2 and S3). TP53 p.R181C was among the first inherited mutations of TP53 reported in the literature, in a family with early onset breast cancer and melanotic spindle cell cancer of the mediastinum. 14 It was described recently in a family of unspecified ancestry with breast cancer, melanoma and renal cell cancer 15 and in other Palestinian families with breast cancer. 9 It has also been reported as a somatic mutation in a breast cancer patient with an inherited BRCA1 mutation. 16 None of the Palestinian families that harbor TP53 p.R181C, either in this study or those previously reported, fulfill clinical criteria for Li-Fraumeni syndrome. 9, 17 Of the breast cancer patients in this project with this mutation, the average age at diagnosis was 38 years, but penetrance was incomplete. In family MK7, which includes genotyped family members in three generations (Fig. 2) , sisters III-6, III-8 and III-10 and maternal aunt II-7 carry the mutation and were diagnosed with breast cancer at ages 29, 30, 32 and 47. However, mutation carriers II-2 and II-5 from the previous generation remain cancer-free at ages 55 and 68. Furthermore, sister III-5, diagnosed with breast cancer at age 32, does not carry the mutation. Haplotype analysis of III-5 is consistent with her carrying the maternal wild-type allele of TP53 (supporting information Fig. S1 ). Evaluation of DNA from III-5 by both BROCA and whole exome sequencing yielded genotypes consistent with her relationship in the family, but with no indication of an alternate explanation for her early onset breast cancer.
Mutations in BRCA1 and BARD1 RING domains
Three other missense mutations-BRCA1 p.H41Y, BRCA1 p.C44F and BARD1 p.C83R-alter critical cysteine or histidine residues of the ring domain (RING) domains of BRCA1 and BARD1. Each of these mutations was found in one Palestinian patient, each with a family history of young onset breast cancer and/or ovarian cancer (Fig. 3) . None appeared in Palestinian controls. BRCA1 p.C44F has been classified as pathogenic by ClinVar, as has BRCA1 p.H41R, which did not appear among the Palestinian patients but alters same residue as BRCA1 p.H41Y. All mutations of the critical zincbinding residues of the BRCA1 and BARD1 RING domains that have been tested experimentally have been shown to abrogate protein function, by being defective in homologydirected DNA repair, destabilizing the BRCA1-BARD1 heterodimer, and/or altering its ubiquitination function of the BRCA1/BARD1 heterodimer. [18] [19] [20] [21] Incidence of breast and ovarian cancer in the families of carriers of these mutations is similar to that in Palestinian families with truncating mutations in BRCA1 and BARD1.
Discussion
The study of inherited breast cancer among Palestinian patients offers insights into mutation profiles in a population not previously studied in this way, reveals new features of inherited missense mutations of TP53, and suggests a contribution to cancer control in this region. The profile of damaging mutations in breast cancer genes among Palestinian patients is noteworthy in its combination of two features: a high level of genetic heterogeneity and a major role for recurrent or founder alleles. Heterogeneity is reflected in the 40 different mutations found among 61 mutation carriers. The importance of recurrent or founder alleles is reflected in the observation that 11 of these 40 mutations explain more than half (36/61) of all patients with Table 2 . Patients with damaging mutations in the mutation discovery cohort 
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mutations from the discovery series. This combination is characteristic of many European countries. 22 In the world generally, the proportion of a disease in any one geographic area explained by founder alleles is likely to decrease over the next generation as young people migrate worldwide and take their alleles with them. Fortunately, given the ease with which all mutations in all breast cancer genes can now be identified, the role of founder alleles is historically interesting but of diminishing clinical importance.
The high frequency of TP53 p.R181C among Palestinian breast cancer patients offers an opportunity to better understand inherited TP53 missense alleles. We agree with the suggestion 9 that TP53 p.R181C is a hypomorphic TP53 mutation primarily increasing risk of breast cancer. TP53 p.R181C is significantly more frequent among familial and young onset Palestinian breast cancer cases than among Palestinian controls, and is responsible for 15% of breast cancer in this group of patients. This mutation therefore has a substantial impact on breast cancer incidence among Palestinian women. On the other hand, penetrance is clearly incomplete, both in the families in this study and those reported previously. Too few families have yet been evaluated to have a robust estimate of risk, but those studied so far suggest that breast cancer risk by age 60 among carriers of this mutation may be between 50 and 75%.
TP53 p.R181C is located in the TP53 DNA-binding domain, a region of the protein that harbors mutations causing Li-Fraumeni syndrome. However, families with this mutation do not fulfill Li-Fraumeni syndrome criteria. These observations are consistent with the complex physiological and biochemical consequences of this mutation with respect to carcinogenesis. Mutant TP53 p.R181C protein almost completely retains the capacity to suppress proliferation and to transcriptionally activate TP53 target genes p21 and mdm2. 23 On the other hand, TP53 p.R181C fails to transactivate proapoptotic genes BAX and IGFBP-3, and induction of apoptosis is only 30-40% that of wild-type levels. 20 Studies at the National Institutes of Health of persons heterozygous for TP53 p.R181C demonstrated that mitochondrial respiration in myoblasts was significantly higher among mutation carriers than among their relatives without the mutation, and that mutation carriers had higher levels of mitochondrial respiratory proteins. 13 TP53 is known to regulate mitochondrial biogenesis through mitochondrial transcription factor A (TFAM) and synthesis of cytochrome c oxidase 2 (SCO2). Both TFAM and SCO2 were present at higher levels in myoblasts of carriers of TP53 p.R181C or the Li-Fraumeni mutation TP53 p.R273H, compared to myoblasts of relatives with wild-type alleles. 13 These observations suggested that carriers of TP53 p.R181C have increased capacity for oxidative phosphorylation, potentially providing cancer cells with survival and proliferative advantages. 13 With respect to its role in the Palestinian population, it has been suggested that TP53 p.R181C is reminiscent of the TP53 p.R337H mutation in Brazil. 9, 24 Women who carry TP53 p.R337H are at increased risk of breast cancer, but penetrance of breast cancer is incomplete, and most families with this mutation do not fulfill Li-Fraumeni syndrome criteria. In Southern Brazil the population prevalence of TP53 p.R337H is 0.3%, where it results in a high rate of adrenocortical tumors in children. 24 However, TP53 p.R337H is associated with a lower penetrance of other cancers than are conventional TP53 mutations. 25 More TP53 mutations with effects such as those of R181C and R337H are likely to be encountered as gene panel testing becomes widely used and TP53 analysis is no longer limited to rare families fulfilling Li-Fraumeni syndrome criteria or to women diagnosed with breast cancer before age 35.
26
Finally, the frequency of mutations in breast cancer genes among Palestinian patients suggests public health actions that could be life-saving. Among patients with either young onset breast cancer or a family history of breast or ovarian cancer, the proportion carrying a mutation in BRCA1 or BRCA2 was 7%, the proportion carrying TP53 p.R181C was 2%, and the proportion carrying a pathogenic mutation in any breast cancer gene was 13%. Knowledge of a patient's genotype both informs her own treatment and enables testing with appropriate follow-up to be offered to her female relatives. 27 Given the efficiency and widespread availability of testing for all classes of mutations in all known breast cancer genes, we suggest that all young or familial patients be offered this service.
